SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
- MitoCareX Bio, a venture of SciSparc Ltd., is focusing on drug discovery and cancer therapeutics targeting the mitochondrial SLC25 protein family.
- Several small molecules with potential anti-cancer properties were identified through virtual screening and confirmed via in-vitro testing.
- MitoCareX is working on developing a predictive AI model to navigate chemical spaces more efficiently and discover novel anti-cancer scaffolds targeting the SLC25 protein.
- None.
Insights
The announcement by MitoCareX Bio regarding the development of a predictive AI model for drug discovery is a significant stride in the pharmaceutical industry, particularly in the oncology segment. The ability to screen millions of small molecules and identify potential anti-cancer treatments is a game-changer. It suggests a substantial enhancement in the efficiency of the drug discovery process, which traditionally is time-consuming and costly.
From a medical research perspective, targeting the mitochondrial SLC25 protein family is a novel approach. The mitochondria play a crucial role in energy production and apoptosis and their dysfunction is associated with various diseases, including cancer. An AI model that can predict the efficacy of small molecules on this target could lead to breakthroughs in cancer therapeutics.
The implications for stakeholders are profound. If the AI model proves to be successful, it could reduce the time and financial resources required for the development of new drugs, potentially leading to a quicker time-to-market for new cancer treatments. This could have a positive impact on the company's financials and be of significant interest to investors and healthcare providers.
Investment in AI for drug discovery is a trend that is picking up momentum in the biotechnology sector. MitoCareX Bio's advancement in creating a predictive AI model signifies not only progress in cancer research but also showcases the potential for AI to revolutionize the drug development pipeline. By validating virtual screening results with in-vitro systems, MitoCareX is setting a precedent for computational and experimental synergy.
The biotech industry often faces high attrition rates in drug development, with many compounds failing to make it past clinical trials. The use of AI to predict successful small molecule candidates could significantly reduce these attrition rates. For the stock market and potential investors, this represents a reduction in risk and could lead to increased confidence in investing in companies like MitoCareX Bio.
Furthermore, the ability to navigate broader chemical spaces more efficiently could result in a diversified portfolio of drug candidates, mitigating the risk of over-reliance on a single compound or therapeutic area. This diversification is a positive signal to the market, potentially leading to a more stable and attractive investment profile for the company.
The pharmaceutical market is intensely competitive, with companies constantly seeking ways to innovate and streamline their R&D processes. MitoCareX Bio's initiative to incorporate AI into their drug discovery process could position them favorably in the market, especially if they are able to identify novel anti-cancer scaffolds that are both effective and unique.
Market exclusivity through patents is a critical component of pharmaceutical strategy. If MitoCareX's predictive AI model leads to the discovery of new scaffolds that can be patented, it could secure a significant competitive advantage and possibly command premium pricing for their therapeutics. This would have a direct impact on the company's revenue and market share.
In the long term, the success of such AI-driven initiatives could catalyze a shift in industry norms, with more companies adopting similar technologies to stay competitive. This could lead to a surge in demand for AI and data analytics expertise within the pharmaceutical industry, influencing job markets and investment trends.
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently
TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. ("MitoCareX "), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, revealed that millions of small molecules were virtually screened using its computationally advanced drug discovery platform, with several molecules identified as potential anti-cancer treatments.
By using its in-vitro screening systems related to the mitochondria, MitoCareX corroborated its virtual findings by confirming the anti-cancer biological activity of several small molecule structures.
Additionally, by utilizing the extensive virtual data generated, MitoCareX working towards creating a predictive AI model. This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses that MitoCareX is working towards creating a predictive AI model and that such model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target the SLC25 protein of interest. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the specialty of SciSparc Ltd. (Nasdaq: SPRC)?
What is the focus of MitoCareX Bio Ltd. within SciSparc?
How did MitoCareX Bio identify potential anti-cancer treatments?
What is MitoCareX Bio working on developing?
